RxDoctor Payments Data

Christine Conner, APRN

Family · Joplin, MONPI 1295120533

Payments from drug & device makers

$2,022in general payments, 2019–2025

Across 99 payments — averaging $20.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$755
  • GSK$322
  • Boehringer Ingelheim$214
  • Sanofi$207
  • Regeneron Healthcare Solutions, Inc.$158
  • Jazz Pharmaceuticals Inc.$41
  • plus $326 from 13 others

What the payments were for

  • Food & beverage$1,94896%
  • Education$744%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,022 in reported general payments places this provider in the 80th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$60,265
Medicare patients
278
Services billed
627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breztri AerosphereBudesonide/Glycopyr/Formoterol236$168,173
Trelegy ElliptaFluticasone/Umeclidin/Vilanter218$164,423
XolairOmalizumab21$51,177
Spiriva RespimatTiotropium Bromide64$38,738
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr51$24,650
Stiolto RespimatTiotropium Br/Olodaterol Hcl28$17,176
Advair HfaFluticasone Propion/Salmeterol42$16,317
SymbicortBudesonide/Formoterol Fumarate38$15,831
Fluticasone-SalmeterolFluticasone Propion/Salmeterol79$9,295
Spiriva HandihalerTiotropium Bromide12$9,017
Albuterol Sulfate HfaAlbuterol Sulfate345$7,014
Breo ElliptaFluticasone/Vilanterol13$6,660
Incruse ElliptaUmeclidinium Bromide12$6,294
Bevespi AerosphereGlycopyrrolate/Formoterol Fum12$5,090
Levocetirizine Dihydrochloride332$3,439

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$322$202,028294 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$755$189,094286 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$214$55,91492 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,812 family providers in Missouri.

Other family in Joplin

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →